Esthesioneuroblastoma other imaging findings: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
===Nuclear Medicine=== | ===Nuclear Medicine=== | ||
As with other neuroblastomas, olfactory neuroblastomas are -meta-iodobenzylguanidine, MIBG avid. This potentially helps to differentiate them from other tumors that arise in the region. | As with other neuroblastomas, olfactory neuroblastomas are -meta-iodobenzylguanidine, MIBG avid. This potentially helps to differentiate them from other tumors that arise in the region. | ||
===Nasal Endoscopy=== | |||
Nasal endoscopy is helpful for evaluating tumor location, extent and characteristics, as well as for obtaining a biopsy. | |||
===Scintigraphy=== | |||
Since the majority of esthesioneuroblastomas express somatostatin receptors, the use of scintigraphy with a radiolabeled somatostatin analog (111 In-pentoctreotide [111 In-DTPA-D-pheoctreotide]; Octreoscan) has been postulated. This technique has been found to be clinically useful, especially for discriminating between postoperative changes and recurrent or residual tumor after extensive skull base surgery.<ref name="pmid16470879">{{cite journal| author=Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D et al.| title=Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. | journal=Head Neck | year= 2006 | volume= 28 | issue= 4 | pages= 305-12 | pmid=16470879 | doi=10.1002/hed.20356 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16470879 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 05:56, 27 January 2016
|
Esthesioneuroblastoma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Esthesioneuroblastoma other imaging findings On the Web | |
|
American Roentgen Ray Society Images of Esthesioneuroblastoma other imaging findings | |
|
Risk calculators and risk factors for Esthesioneuroblastoma other imaging findings | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Other imaging studies for esthesioneuroblastoma include angiography/digital subtraction angiography and nuclear medicine.[1]
Other Imaging Findings
Other imaging studies for esthesioneuroblastoma include angiography/digital subtraction angiography and nuclear medicine.[1]
Angiography/Digital subtraction angiography (DSA)
Angiography demonstrates a prominent tumour blush with arteriovenous shunting, and persistent opacification.
Nuclear Medicine
As with other neuroblastomas, olfactory neuroblastomas are -meta-iodobenzylguanidine, MIBG avid. This potentially helps to differentiate them from other tumors that arise in the region.
Nasal Endoscopy
Nasal endoscopy is helpful for evaluating tumor location, extent and characteristics, as well as for obtaining a biopsy.
Scintigraphy
Since the majority of esthesioneuroblastomas express somatostatin receptors, the use of scintigraphy with a radiolabeled somatostatin analog (111 In-pentoctreotide [111 In-DTPA-D-pheoctreotide]; Octreoscan) has been postulated. This technique has been found to be clinically useful, especially for discriminating between postoperative changes and recurrent or residual tumor after extensive skull base surgery.[2]
References
- ↑ 1.0 1.1 Esthesioneuroblastoma. Radiopedia(2015) http://radiopaedia.org/articles/olfactory-neuroblastoma Accessed on January 25, 2016
- ↑ Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D; et al. (2006). "Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression". Head Neck. 28 (4): 305–12. doi:10.1002/hed.20356. PMID 16470879.